| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.006 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.006 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.17 | 0.007 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.007 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.007 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.088 | 0.008 |
| mRNA | 16-beta-bromoandrosterone | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |